Posted by Michael Wonder on 20 Sep 2022
European Medicine Agency accepts marketing authorisation applications for bimekizumab in psoriatic arthritis and axial spondyloarthritis
20 September 2022 - First regulatory submissions for bimekizumab in psoriatic arthritis and axial spondyloarthritis worldwide.
UCB today announced that the EMA has accepted for regulatory review the two marketing authorisation applications for bimekizumab for the treatment of adult patients with active psoriatic arthritis and adult patients with active axial spondyloarthritis.
